Shanghai Hyundai pharmaceutical invests in the finance of Sinopharm and accelerates the industrial integration

On September 27, Shanghai Hyundai Pharmaceutical Co., Ltd released the announcement of Shanghai Hyundai Pharmaceutical Co., Ltd on foreign investment and related transactions, saying that it, together with China Pharmaceutical Group Co., Ltd (hereinafter referred to as "Sinopharm group") and its subordinate related parties, jointly increased the capital of Sinopharm Group Finance Co., Ltd (hereinafter referred to as "Sinopharm finance") The key contents include but are not limited to: Shanghai Modern Pharmaceutical Co., Ltd (hereinafter referred to as "the company") plans to jointly increase the capital of Sinopharm Group Finance Co., Ltd (hereinafter referred to as "Sinopharm finance") with China Pharmaceutical Group Co., Ltd (hereinafter referred to as "Sinopharm group") and its subordinate related parties All parties involved in this transaction are controlled by Sinopharm group and constitute related transactions The capital increase of Sinopharm finance is based on the evaluation report issued by Shanghai Dongzhou assets evaluation Co., Ltd Among them, the company plans to invest 200 million yuan with its own capital, and after the capital increase, Hyundai pharmaceutical will hold 10.9091% equity of Sinopharm finance This connected transaction has been deliberated and approved at the 28th (Interim) meeting of the sixth board of directors of the company The connected directors Mr Zhou Bin, Mr Li Zhiming, Mr Dong Zenghe, Mr Wei Baokang and Ms Li Xiaojuan avoided voting, and the remaining four non connected directors participated in voting The independent directors approved the connected transaction in advance and expressed independent opinions In the past 12 months, the amount of related party transactions between the company and Sinopharm group and its subsidiaries was RMB 1551598500, not exceeding the estimated amount approved by the annual general meeting of shareholders In the past 12 months, the company has not engaged in any foreign investment related to related parties According to the Listing Rules of Shanghai Stock Exchange and the articles of association, this connected transaction does not need to be submitted to the general meeting of shareholders for deliberation The financial capital increase of Sinopharm will not take effect until it is approved by the Beijing regulatory bureau of the Insurance Regulatory Commission of the Bank of China For details of the rest, please see the attachment: announcement of Shanghai Modern Pharmaceutical Co., Ltd on foreign investment and related party transactions.pdf this article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprinting is to transmit more information and does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.